Skip to content
Cyclodextrin News

Cyclodextrin News

A forum for researchers, students and applicants in the field of cyclodextrin technology

  • Home
  • Pharma applications
  • Non-pharma applications
  • CD derivatives
  • Events
  • E-ducation

Tag: Cholesterol

July 20, 2026 CD as API / Life sciences / Pharma applications

HPBCD for the treatment of irreversible white matter injury

White matter repair relies on microglial clearance of cholesterol-rich myelin debris. Microglia have been reported to predominantly depend on de

Continue reading

June 17, 2026 Life sciences / Pharma applications

Environment-Sensitive Fluorophores Report on Structural Organization of Biological Membranes at Various Depths

Molecular-order-related membrane biophysical properties contribute to the functional modulation of transmembrane proteins, and therefore, their changes due to a modified

Continue reading

June 3, 2026 CD as API / CD derivatives / Drug delivery / Pharma applications

Nano-Enabled Toxicity of Pharmaceutical Excipients

Nanotechnology has brought revolutionary advances in the pharmaceutical field. Among drug delivery systems, nanocarriers, which enhance the solubility, stability and

Continue reading

May 27, 2026 CD as API / Pharma applications

Cyclarity Unveils First-Ever Clinical Data Demonstrating Excretion of Oxidized Cholesterol, at American Heart Association Vascular Discovery Scientific Sessions

 Cyclarity Therapeutics, Inc., a clinical stage biopharmaceutical company engineering cyclodextrin molecules into simple, scalable, and affordable therapies that bind and

Continue reading

May 18, 2026 CD as API / Pharma applications

HPBCD against acute and subacute infarcts in a mouse model of ischemic stroke

HPβCD has also been investigated as an active pharmaceutical ingredient (API) for the prospective treatment of ischemic stroke. We previously

Continue reading

April 6, 2026 CD as API / Pharma applications

HPβCD’s Promise in Treating Ischemic Stroke

Ischemic stroke is a leading cause of mortality and long-term disability worldwide, with limited pharmacological interventions available. 2-hydroxypropyl-β-cyclodextrin (HPβCD), a

Continue reading

February 9, 2026 CD as API / Drug delivery / Pharma applications

CDs for Regulating Cholesterol Homeostasis in Atherosclerosis

The progression of atherosclerosis (AS) is strongly linked to lipid crystals accumulation caused by cholesterol metabolism disorders and the worsening

Continue reading

February 4, 2026 CD as API / CD derivatives / Pharma applications

Studies on Sleep-Deprived Animals Reveal HPBCD’s Role in Restoring Normal Neuronal Function

A study published in Proceedings of the National Academy of Sciences (https://www.pnas.org/doi/10.1073/pnas.2523438123) suggests that lack of sleep harms the fatty insulation that

Continue reading

December 26, 2025 CD as API / Drug delivery / Pharma applications

Neuroprotective effects of statins and cyclodextrins: review and potential role in dementia treatment

Dementia is a progressive and irreversible deterioration in cognition that has a significant impact on the person’s activities of daily

Continue reading

a rat is standing on top of a plastic container
December 18, 2025 CD as API / CD derivatives / Pharma applications

Selective removal of 7-ketocholesterol by a CD-dimer, a novel atherosclerosis therapeutic candidate

The removal of the toxic oxidized cholesterol, 7-ketocholesterol (7KC), from cells through the administration of therapeutics has the potential to

Continue reading

Posts pagination

1 2 3 … 14 Next Posts»

Recent Posts

  • In Vitro and Ex Vivo Studies on the Absorption and Distribution of β-Cyclodextrin Polymer
  • Positively Charged Fluorine-Free Cyclodextrin Nanosponges for PFAS Removal
  • Impact of Cholesterol Depletion by methyl BCD on Dopamine Transmission Dynamics in Brain
  • Special Issue “Cyclodextrin-Functionalized Materials for Drug Delivery, Pharmaceutical and Medical Applications”
  • Cyclodextrin-Based Oral Solution of Ursodeoxycholic Acid Using a Ready-to-Use Vehicle

Tags

alpha-CD Alzheimer disease atherosclerosis Cancer therapy Captisol Cholesterol Clinical trial conference Covid-19 cyclodextrin polymer Dexolve drug delivery drug delivery systems electrospinning FDA Food gamma-CD Gilead HPBCD hydrogel methyl BCD Nanoparticles Niemann Pick Disease RAMEB remdesivir review SBECD Special issue Synthesis

Follow Us

  • LinkedIn
  • X
  • Facebook

Categories

  • Agriculture (27)
  • Analysis (72)
  • CD as API (351)
  • CD derivatives (424)
  • Cosmetics and toilettry (52)
  • Diagnosis (13)
  • Drug delivery (804)
  • E-ducation (63)
  • Environmental (141)
  • Events (236)
  • Food (229)
  • Gene delivery (22)
  • Household products (5)
  • Household products (1)
  • In Hungarian (4)
  • Life sciences (44)
  • Non-pharma applications (409)
  • Other industrial use (110)
  • Pharma applications (1,202)
  • Supramolecular systems (44)
  • Uncategorized (161)

Top Posts

  • Positively Charged Fluorine-Free Cyclodextrin Nanosponges for PFAS Removal
  • In Vitro and Ex Vivo Studies on the Absorption and Distribution of β-Cyclodextrin Polymer
  • CDs for the removal of PFAS; A review
  • 22nd International Cyclodextrin Symposium (ICS-22) in India
  • Cyclodextrin polymers containing ionizable and ionic groups: A comprehensive review from classifications and synthesis methods to applications.
  • How air fresheners work?
  • Use of odor-absorbing component, Hydroxypropyl-β-cyclodextrin in a new Japanese personal care product
  • Impact of Cholesterol Depletion by methyl BCD on Dopamine Transmission Dynamics in Brain
  • FDA Grants Approval to HPBCD-Enhanced Biologic: A 'Super-Originator' Formulation
  • The Impact and Prospects of Green Chemistry for Textile Technology

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 4,476 other subscribers
Loading Comments...